Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849074 | 0.87 | NPSR1 (0.58) | TLR7TLR8 | |
| SCHEMBL18054732 | 0.86 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL15305558 | 0.86 | MPO (0.49) | TLR7TLR8 | |
| SCHEMBL2847695 | 0.86 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL16624323 | 0.85 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL6120720 | 0.84 | TLR7 (0.45) | TLR7TLR8 | |
| SCHEMBL22508906 | 0.82 | TLR7 (0.47) | TLR7TLR8 | |
| SCHEMBL6120839 | 0.81 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL853847 | 0.81 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL30037326 | 0.81 | TLR7 (0.48) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077510-B2 | Carboxylic acid compounds | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10562861-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-10562861-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| EP-2850067-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2015-03-25 | — | — | EP | disclosed |
| CN-104302628-A | Carboxylic acid compounds | DAINIPPON SUMITOMO PHARMA CO | 2015-01-21 | — | — | CN | disclosed |
| WO-2013172479-A1 | CARBOXYLIC ACID COMPOUNDS | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-21 | — | — | WO | disclosed |
| WO-2012066336-A1 | BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066336-A1 | BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS | ASTRAZENECA AB (SE) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | TLR7 87/4885TLR8 665/4885 |
| US-12077510-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
| US-11299465-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
| US-10562861-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | TLR7 79/4885TLR8 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.